Prescribing of High‐Risk Medications for Older Adults with Rheumatic Disease
BACKGROUND: Older adults with rheumatic diseases often experience multi-morbidity and polypharmacy, potentially increasing their risk of adverse events from high-risk medications (HRMs). OBJECTIVE: Evaluate the prevalence, characterize HRM prescriptions by prescriber characteristics, and identify patient-level factors associated with HRM prescribing among older adults with rheumatic diseases. DESIGN: National cohort study using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry, linked to Medicare Parts A, B, and D. SETTING: Electronic health record-based data from practices representing approximately one-third of U.S. rheumatologists. PARTICIPANTS: Medicare-enrolled adults ≥65 years with ≥2 visits in 2021 at RISE participating practices and ≥2 ICD-10 codes for selected rheumatic diseases. MEASUREMENTS: The primary outcome was prescription for a HRM. Logistic regression models were used to predict exposure to any HRM using generalized estimating equations to account for clustering of patients within practices. RESULTS: Among 45,455 older adults (mean age 75.8±6.4 years; 76.9% female), 13,977 (30.7%) received ≥1 HRM. Prescriptions predominantly originated from non-rheumatology clinicians (82.3%). Common HRMs included skeletal muscle relaxants, first-generation antihistamines, antidepressants with strong anticholinergic activity, non-benzodiazepine benzodiazepine receptor agonist hypnotics ("Z-drugs"), and antispasmodics. In adjusted analyses, patients with axial spondyloarthritis (OR 1.40, 95%CI 1.20-1.62) and Sjögren's disease (OR 1.39, 95%CI 1.04-1.86) had the highest odds of receiving a HRM compared with rheumatoid arthritis. CONCLUSIONS: High-risk medications are frequently prescribed to older adults with rheumatic diseases, exceeding the prevalence reported in the general Medicare population. These findings highlight the need for individualized medication review and enhanced cross-specialty collaboration when managing this population.
Authors
- Jinoos Yazdany (ORCID: https://orcid.org/0000-0002-3508-4094)
- Gabriela Schmajuk (ORCID: https://orcid.org/0000-0003-2687-5043)
- Rachael Stovall (ORCID: https://orcid.org/0000-0002-0355-4020)
- Michael Alan Steinman (ORCID: https://orcid.org/0000-0002-9564-9480)
- Christine Anastasiou (ORCID: https://orcid.org/0000-0002-3074-2529)
- Karen H. Costenbader (ORCID: https://orcid.org/0000-0002-8972-9388)
- Eric M. Roberts (ORCID: https://orcid.org/0009-0005-8435-8994)
- Stephen Shiboski
- Daniel Ciccarone
Institutions
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- University of Washington (US)
- University of California San Francisco Medical Center (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1002/art.70400
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rheumatology Research Foundation
- National Institutes of Health
- Agency for Healthcare Research and Quality
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases